Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.38 |
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11299490 | 1.00 | VCAM1 (0.39) | VCAM1ALDH1A1MAPTTDP1ATM | |
| SCHEMBL30597619 | 0.89 | MAPT (0.35) | VCAM1ALDH1A1MAPTTDP1ATM | |
| SCHEMBL1014334 | 0.89 | MAPT (0.35) | VCAM1ALDH1A1MAPTTDP1ATM | |
| SCHEMBL1014335 | 0.89 | MAPT (0.35) | VCAM1ALDH1A1MAPTTDP1ATM | |
| SCHEMBL8487352 | 0.84 | KMT2A (0.49) | ALDH1A1MAPTTDP1POLBRAB9A | |
| SCHEMBL18152717 | 0.83 | ERN1 (0.42) | VCAM1ALDH1A1MAPTPOLBRAB9A | |
| SCHEMBL18152719 | 0.83 | ERN1 (0.42) | VCAM1ALDH1A1MAPTPOLBRAB9A | |
| SCHEMBL8488539 | 0.83 | MAPT (0.46) | VCAM1ALDH1A1MAPTTDP1POLB | |
| SCHEMBL26800247 | 0.82 | VCAM1 (0.40) | VCAM1ALDH1A1MAPTTDP1POLB | |
| SCHEMBL26115663 | 0.82 | CYP3A4 (0.51) | ALDH1A1MAPTTDP1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665707-B1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-01-18 | — | — | EP | disclosed |
| EP-2665707-B1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-01-18 | — | — | EP | disclosed |
| US-9403807-B2 | Mineralocorticoid receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403807-B2 | Mineralocorticoid receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150284376-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284376-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-10-08 | — | — | US | disclosed |
| US-8933113-B2 | Mineralocorticoid receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933113-B2 | Mineralocorticoid receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130331419-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2013-12-12 | — | — | US | disclosed |
| EP-2665707-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012097744-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012097744-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284376-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, CYP21A2 | VCAM1 965/4885ALDH1A1 691/4885MAPT 3602/4885 |
| US-20130331419-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, CYP21A2 | VCAM1 620/4885ALDH1A1 415/4885MAPT 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.